DCAN remains overlooked as an important risk factor for cardiac morbidity and mortality in diabetes.
Veronica Hackethal, MD
The EMPA-REG OUTCOME trial explored the effect of empagliflozin on improving heart failure outcomes across a variety of type 2 diabetes patients.
SGLT2 inhibitors are known to lower blood pressure, but how best to use these drugs with blood pressure lowering medications remains an open question.
This study is the first to look at all-cause and cardiovascular mortality in type 2 diabetes patients after bariatric surgery.
Researchers examined the effect neighborhood disadvantage and race play in metabolic control and inflammation in children with type 1 diabetes.
Older patients with type 2 diabetes are a highly variable population with different requirements for diabetes management.
The past 30 years have witnessed major advances in PCI; fewer changes have occurred with CABG, though the death rate has decreased. Which is better?
The hormonal changes of adolescence can wreak havoc on glucose control, but what else can affect disease management in teens?
Although information on the safety and efficacy of CAM is a murky area full of conflicting, inconclusive evidence, certain types of CAM do hold promise, and may deserve consideration.
The rise of type 1 diabetes rates corresponds with the widespread practice of childhood vaccinations in developed countries – coincidence or not?